Biotech & Pharma

Is Targeted Protein Degradation the "Break" Neurology Needs?

24 sec read6 views0 listens

Targeted protein degradation using PROTACs is showing promise in treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, particularly through the targeting of LRRK2 proteins. This development matters because it offers a more precise approach to modulating disease biology compared to traditional small-molecule inhibitors, potentially leading to more effective treatments for complex neurological disorders.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets4 days ago22 sec read

Kodeon acquires mental wellness app Breethe in largest acquisition to date

Toronto-based Kodeon has acquired Montréal’s mental wellness platform Breethe, marking its largest acquisition and expanding its portfolio of mobile life-improvement apps. This move is significant for developers as it highlights the growing importanc...

Ali Nemati

Biotech & PharmaJul 2028 sec read

Protein Protects Against Tau Tangles, Synaptic Loss in Mouse Model of Tauopathy

Scientists at Sanford Burnham Prebys have discovered that the SORLA protein protects against tau tangles and synaptic loss in a mouse model of tauopathy, suggesting potential new treatments for Alzheimer’s disease. This finding is significant as it i...

Ali Nemati

Real Estate & HomeJul 2026 sec read

Nurse Lindsay Clancy Set To Go on Trial for Murder of Her 3 Children-More Than 3 Years After They Were Found Dead at Massachusetts Home

Lindsay Clancy's murder trial for killing her three children begins in Massachusetts after more than three years since the incident. The case centers on whether she should be held criminally responsible due to postpartum psychosis, a critical issue f...

Ali Nemati